WHEN OBESITY IS HARD TO FIGHT: HOMOZYGOUS POMC MUTATION IN A HISPANIC MALE
Abstract
POMC is a well-studied polypeptide that plays a key role in several crucial body functions. An error in this gene may lead to problems such as adrenal insufficiency, hypopigmentation, obesity, hypogonadotropic hypogonadism, and more. Since genetic testing has become more common, POMC has been targeted for therapeutic interventions that are now widely available for use as treatment. This report demonstrates how genetic testing was utilized to obtain several diagnoses early in life accurately and how that knowledge led to appropriate treatment. Genetic testing can be a powerful tool for physicians; accurate diagnosis directs available therapeutics, tremendously decreases comorbidities, and improves disease outcomes.
References
2. Obesity and overweight [Internet]. Who.int. [cited 2022 Jul 8]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
3. Biebermann H, Kühnen P, Kleinau G, Krude H. The neuroendocrine circuitry controlled by POMC, MSH, and AGRP. Handb Exp Pharmacol [Internet]. 2012 [cited 2022 Jul 8];(209):47–75. Available from: https://pubmed.ncbi.nlm.nih.gov/22249810/.
4. Çetinkaya S, Güran T, Kurnaz E, Keskin M, Sağsak E, Savaş Erdeve S, et al. A patient with proopiomelanocortin deficiency: An increasingly important diagnosis to make. J Clin Res Pediatr Endocrinol [Internet]. 2018 [cited 2022 Jul 8];10(1):68–73. Available from: http://dx.doi.org/10.4274/jcrpe.4638.
5. Gregoric N, Groselj U, Bratina N, Debeljak M, Zerjav Tansek M, Suput Omladic J, et al. Two cases with an early presented proopiomelanocortin deficiency-A long-term follow-up and systematic literature review. Front Endocrinol (Lausanne) [Internet]. 2021;12:689387. Available from: http://dx.doi.org/10.3389/fendo.2021.689387
6. FDA approves first treatment for weight management for people with certain rare genetic conditions [Internet]. U.S. Food and Drug Administration. FDA; [cited 2022 Jul 8]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions.
Copyright (c) 2022 Journal of Internal Medicine: Science & Art
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
